Should you buy Prestige Consumer Healthcare In (PBH)?
Updated
Prestige Consumer Healthcare trades at a forward P/E of 9.3x with analyst upside of 25% and strong operating margins of 17%, but has missed earnings estimates in all 4 of the last 4 quarters with estimates trending downward — making the value case dependent on a fundamental turnaround that has not yet materialized.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
At a forward P/E of 9.3x and analyst upside of 25% to roughly $58, Prestige Consumer Healthcare offers an attractive entry price relative to its 17% operating margin and 8/9 Piotroski F-Score, suggesting the market is overly penalizing the earnings miss streak. Valuation breakdown | Price rises above $55 within 12 months as the valuation discount is recognized once the earnings miss streak ends. | →Stable |
| CounterFour consecutive earnings misses averaging negative 7% surprise, combined with declining revenue of 5% year over year, suggest estimates are still too high rather than the stock being undervalued. | ||
Despite four consecutive earnings misses, Prestige Consumer Healthcare maintains strong operating margins at 17% with free cash flow at 71% of net income and a Piotroski F-Score of 8/9, indicating the business quality floor is intact. Quality breakdown | Operating margin stays above 14% for at least 3 of the next 4 quarters, confirming the margin floor holds despite revenue pressure. | →Stable |
| CounterRevenue has declined 5% year over year and earnings estimates are trending downward; margin compression typically follows revenue decline in consumer healthcare as fixed overhead becomes a larger proportion of a shrinking sales base. | ||
The four consecutive earnings misses averaging negative 7% have already reset expectations significantly lower; the risk of a positive EPS surprise grows as estimates converge toward the true earnings run rate. Earnings | Earnings beat consensus by more than 3% in at least 1 of the next 2 quarters, signaling the miss streak is ending. | →Stable |
| CounterEstimates trending downward means the market is still adjusting expectations lower; a company that misses by 11.5% and then 11.3% in consecutive quarters may still not have reached bottom estimates. | ||
At a forward P/E of 9.3x and analyst upside of 25% to roughly $58, Prestige Consumer Healthcare offers an attractive entry price relative to its 17% operating margin and 8/9 Piotroski F-Score, suggesting the market is overly penalizing the earnings miss streak.
→Stable- Expectation
- Price rises above $55 within 12 months as the valuation discount is recognized once the earnings miss streak ends.
CounterFour consecutive earnings misses averaging negative 7% surprise, combined with declining revenue of 5% year over year, suggest estimates are still too high rather than the stock being undervalued.
Despite four consecutive earnings misses, Prestige Consumer Healthcare maintains strong operating margins at 17% with free cash flow at 71% of net income and a Piotroski F-Score of 8/9, indicating the business quality floor is intact.
→Stable- Expectation
- Operating margin stays above 14% for at least 3 of the next 4 quarters, confirming the margin floor holds despite revenue pressure.
CounterRevenue has declined 5% year over year and earnings estimates are trending downward; margin compression typically follows revenue decline in consumer healthcare as fixed overhead becomes a larger proportion of a shrinking sales base.
The four consecutive earnings misses averaging negative 7% have already reset expectations significantly lower; the risk of a positive EPS surprise grows as estimates converge toward the true earnings run rate.
→Stable- Expectation
- Earnings beat consensus by more than 3% in at least 1 of the next 2 quarters, signaling the miss streak is ending.
CounterEstimates trending downward means the market is still adjusting expectations lower; a company that misses by 11.5% and then 11.3% in consecutive quarters may still not have reached bottom estimates.
▸ Show 1 more pillar▾ Show fewer
Despite the confirmed death cross and downtrend, the MACD has improved to a score of 10 — the highest possible reading — suggesting a technical inflection may be forming even as price remains below key moving averages.
→Stable- Expectation
- Price crosses above the 200-day moving average within 9 months and sustains above that level for at least 20 consecutive trading days.
CounterMACD improvement in a stock with four consecutive earnings misses and declining revenue is unreliable as a fundamental inflection signal; the price remains near 52-week lows at only 0.4% above the annual trough.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1At a forward P/E of 9.3x and analyst upside of 25% to roughly $58, Prestige Consumer Healthcare offers an attractive entry price relative to its 17% operating margin and 8/9 Piotroski F-Score, suggesting the market is overly penalizing the earnings miss streak.
Trip ifAnalyst consensus price target falls below $45 for 2 consecutive months, eliminating the valuation discount thesis.
- P2Despite four consecutive earnings misses, Prestige Consumer Healthcare maintains strong operating margins at 17% with free cash flow at 71% of net income and a Piotroski F-Score of 8/9, indicating the business quality floor is intact.
Trip ifOperating margin falls below 12% for 2 consecutive quarters, breaking the margin quality floor.
- P3The four consecutive earnings misses averaging negative 7% have already reset expectations significantly lower; the risk of a positive EPS surprise grows as estimates converge toward the true earnings run rate.
Trip ifEarnings miss consensus by more than 5% for a 5th consecutive quarter, extending the miss streak further.
- P4Despite the confirmed death cross and downtrend, the MACD has improved to a score of 10 — the highest possible reading — suggesting a technical inflection may be forming even as price remains below key moving averages.
Trip ifPrice drops below $40 and holds below that level for more than 10 trading days, invalidating the MACD recovery thesis.
How the engine reached this verdict
TrendMatrix's engine output for Prestige Consumer Healthcare In (PBH) is SELL_IF_HOLDING with medium conviction, score 5.3/10 at $47.51. The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 3.09 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $47.51, with structural invalidation at $44.18. The asymmetric R:R against a reversal hypothesis is 3.19 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: High-quality business; Attractive valuation; Analyst upside: 22%. On the bear side: Consecutive earnings misses (4); Earnings estimates trending DOWN; Weak growth.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PBH — 10-dimension breakdown →
Bull case
- ▸High-quality business
- ▸Attractive valuation
- ▸Analyst upside: 22%
Bear case
- ▸Consecutive earnings misses (4)
- ▸Earnings estimates trending DOWN
- ▸Weak growth